[Skip to Content]
[Skip to Content Landing]

July 2019 - April 2015

Decade

Year

Issue

October 2015, Vol 1, No. 7, Pages 861-998

Original Investigation

Breast Cancer Mortality After a Diagnosis of Ductal Carcinoma In Situ

Abstract Full Text
free access
JAMA Oncol. 2015;1(7):888-896. doi:10.1001/jamaoncol.2015.2510

In this study using SEER data, the risk of death from stage 0 breast cancer increased after a diagnosis of an ipsilateral second primary invasive breast cancer, but prevention of these recurrences did not reduce 10-year breast cancer mortality.

Dose-Escalated Irradiation and Overall Survival in Men With Nonmetastatic Prostate Cancer

Abstract Full Text
free access
JAMA Oncol. 2015;1(7):897-906. doi:10.1001/jamaoncol.2015.2316

This retrospective analysis of patients with prostate cancer found that dose-escalated external-beam radiation therapy was associated with improved survival in intermediate-risk and high-risk, but not low-risk, disease.

Prognostic Implication of Persistent Human Papillomavirus Type 16 DNA Detection in Oral Rinses for Human Papillomavirus–Related Oropharyngeal Carcinoma

Abstract Full Text
free access
JAMA Oncol. 2015;1(7):907-915. doi:10.1001/jamaoncol.2015.2524

This cohort study of patients with incident human papillomavirus (HPV)–related oropharyngeal carcinoma found that although infrequent, persistent HPV type 16 DNA in posttreatment oral rinses is associated with poor prognosis and is a potential tool for long-term tumor surveillance.

Differences in the Acute Toxic Effects of Breast Radiotherapy by Fractionation Schedule: Comparative Analysis of Physician-Assessed and Patient-Reported Outcomes in a Large Multicenter Cohort

Abstract Full Text
free access has audio
JAMA Oncol. 2015;1(7):918-930. doi:10.1001/jamaoncol.2015.2590

This prospective cohort study of patients with breast cancer receiving hypofractionation vs conventional fractionation for whole-breast radiotherapy found that patients receiving hypofractionation had decreased acute pain and fatigue and were bothered less by dermatitis.

Acute and Short-term Toxic Effects of Conventionally Fractionated vs Hypofractionated Whole-Breast Irradiation: A Randomized Clinical Trial

Abstract Full Text
free access
JAMA Oncol. 2015;1(7):931-941. doi:10.1001/jamaoncol.2015.2666

In this randomized clinical trial, hypofractionated whole-breast irradiation (WBI) appeared to yield lower rates of acute toxic effects than conventionally fractionated WBI as well as less fatigue and less trouble meeting family needs 6 months after radiation therapy.

Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment

Abstract Full Text
open access
JAMA Oncol. 2015;1(7):943-951. doi:10.1001/jamaoncol.2015.2690

In this clinically representative cohort, multigene panel testing for hereditary breast and/or ovarian cancer risk assessment yielded findings likely to change clinical management for substantially more patients than does testing for BRCA1/2 alone.

Brief Report

Mosaic Epigenetic Inheritance as a Cause of Early-Onset Colorectal Cancer

Abstract Full Text
free access
JAMA Oncol. 2015;1(7):953-957. doi:10.1001/jamaoncol.2015.1484

This case report describes a 29-year-old man with early-onset colorectal cancer who showed a constitutional MLH1 epimutation inherited from his asymptomatic mother, who showed methylation on the same allele but in less than 5% of her somatic cells.

Research Letter

Acquired Resistance of EGFR-Mutant Lung Cancer to a T790M-Specific EGFR Inhibitor: Emergence of a Third Mutation (C797S) in the EGFR Tyrosine Kinase Domain

Abstract Full Text
open access
JAMA Oncol. 2015;1(7):982-984. doi:10.1001/jamaoncol.2015.1066

This case report describes a tertiary acquired mutation identified in a clinical lung cancer sample after treatment with a third-generation EGFR tyrosine kinase inhibitor.

Efficacy of Prostate-Specific Antigen Screening: Use of Regression Discontinuity in the PLCO Cancer Screening Trial

Abstract Full Text
free access
JAMA Oncol. 2015;1(7):984-986. doi:10.1001/jamaoncol.2015.2993

This analysis uses regression discontinuity to reexamine results of the Prostate Lung Colorectal and Ovarian cancer screening trial and concludes that using this technique is worthwhile since treatment decisions are often based on discrete cutoffs in continuous data.

Special Communication

Improving Patient Safety in Clinical Oncology: Applying Lessons From Normal Accident Theory

Abstract Full Text
free access
JAMA Oncol. 2015;1(7):958-964. doi:10.1001/jamaoncol.2015.0891

In this special communication, Normal Accident Theory, a framework for analyzing failure potential within and between systems, is applied to the complex interdisciplinary practice of clinical oncology to improve health care safety.

Review

Predicting Prognosis in Chronic Lymphocytic Leukemia in the Contemporary Era

Abstract Full Text
free access
JAMA Oncol. 2015;1(7):965-974. doi:10.1001/jamaoncol.2015.0779

Next-generation sequencing has identified new genetic markers that have altered prognosis for patients with chronic lymphocytic leukemia (CLL) at diagnosis. Nabhan and coauthors discuss the various prognostic parameters in CLL, focusing on cytogenetics, cellular-based factors, and gene mutations.

JAMA Oncology Clinical Challenge

Blurred Vision

Abstract Full Text
JAMA Oncol. 2015;1(7):979-980. doi:10.1001/jamaoncol.2015.2297

A man in his 70s with a history of myeloid leukemia, prostate cancer, and colonic adenocarcinoma presented with acute-onset blurred vision in the left eye; examination revealed bilateral hypopyon. What is your diagnosis?

Viewpoint

Neoadjuvant Therapy in Breast Cancer as a Basis for Drug Approval

Abstract Full Text
JAMA Oncol. 2015;1(7):875-876. doi:10.1001/jamaoncol.2015.1293

The neoadjuvant approach to drug development has great potential, especially when phase 3 trials have adaptive designs that use interim by-treatment information regarding pathological complete response and event-free survival.

Breast Cancer in Young Women: Rare Disease or Public Health Problem?

Abstract Full Text
JAMA Oncol. 2015;1(7):877-878. doi:10.1001/jamaoncol.2015.2112

This Viewpoint discusses the perception and reality of breast cancer incidence in young women and the medical and psychosocial challenges that are unique to young women with breast cancer or accentuated by their age.

Brave-ish New World—What’s Needed to Make Precision Oncology a Practical Reality

Abstract Full Text
JAMA Oncol. 2015;1(7):879-880. doi:10.1001/jamaoncol.2015.1540

This viewpoint examines the positive and negative aspects of broad vs narrow testing for precision cancer medicine.

From the JAMA Network

The Pharmacogenomics of Vincristine-Induced Neuropathy: On Pins and Needles

Abstract Full Text
free access
JAMA Oncol. 2015;1(7):975-976. doi:10.1001/jamaoncol.2015.1173

Who Is Who in Primary Vitreoretinal Lymphoma?

Abstract Full Text
JAMA Oncol. 2015;1(7):977-978. doi:10.1001/jamaoncol.2015.1223
Editorial

Rethinking the Standard for Ductal Carcinoma In Situ Treatment

Abstract Full Text
JAMA Oncol. 2015;1(7):881-883. doi:10.1001/jamaoncol.2015.2607

Dose-Escalated Radiotherapy for Prostate Cancer: Is the Sky the Limit?

Abstract Full Text
JAMA Oncol. 2015;1(7):883-884. doi:10.1001/jamaoncol.2015.2419
Invited Commentary

Persistent Salivary Human Papillomavirus DNA as a Surveillance Biomarker: Not Just Spitting in the Wind

Abstract Full Text
JAMA Oncol. 2015;1(7):915-917. doi:10.1001/jamaoncol.2015.2606

Hypofractionation for Early-Stage Breast Cancer: No More Excuses

Abstract Full Text
JAMA Oncol. 2015;1(7):941-942. doi:10.1001/jamaoncol.2015.2605

This Invited Commentary highlights the importance of hypofractionation dosing for radiation treatment of early-stage breast cancer.

Usefulness of Multigene Testing: Catching the Train That’s Left the Station

Abstract Full Text
JAMA Oncol. 2015;1(7):951-952. doi:10.1001/jamaoncol.2015.2699

This Invited Commentary outlines the benefits and challenges of multigene testing, which is rapidly becoming the norm for genetic cancer risk assessment, and emphasizes the importance of meaningful guidelines for cancer-preventive care for those with less common genetic findings.

JAMA Oncology Patient Page

Performance Status in Patients With Cancer

Abstract Full Text
free access
JAMA Oncol. 2015;1(7):998. doi:10.1001/jamaoncol.2015.3113
Comment & Response

Progesterone and Synthetic Progestin Controversies

Abstract Full Text
JAMA Oncol. 2015;1(7):986-987. doi:10.1001/jamaoncol.2015.2280

Progesterone and Synthetic Progestin Controversies

Abstract Full Text
JAMA Oncol. 2015;1(7):987. doi:10.1001/jamaoncol.2015.2283

Progesterone and Synthetic Progestin Controversies—Reply

Abstract Full Text
JAMA Oncol. 2015;1(7):987-988. doi:10.1001/jamaoncol.2015.2294

Prognosis in Chronic Lymphocytic Leukemia

Abstract Full Text
JAMA Oncol. 2015;1(7):988. doi:10.1001/jamaoncol.2015.2521

Prognosis in Chronic Lymphocytic Leukemia—Reply

Abstract Full Text
JAMA Oncol. 2015;1(7):988-989. doi:10.1001/jamaoncol.2015.2532
Correction

Incorrect Author Name Spelling

Abstract Full Text
free access
JAMA Oncol. 2015;1(7):989. doi:10.1001/jamaoncol.2015.2396

Error in Figure

Abstract Full Text
free access
JAMA Oncol. 2015;1(7):989. doi:10.1001/jamaoncol.2015.3916

Error in Data Presentation in Figure

Abstract Full Text
free access
JAMA Oncol. 2015;1(7):989. doi:10.1001/jamaoncol.2015.3943
JAMA Oncology Masthead

JAMA Oncology

Abstract Full Text
free access
JAMA Oncol. 2015;1(7):865. doi:10.1001/jamaoncol.2014.250
In This Issue of JAMA Oncology

Highlights

Abstract Full Text
free access
JAMA Oncol. 2015;1(7):861. doi:10.1001/jamaoncol.2015.0728
×